Skin Cancer & Melanoma

Latest News

The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.
Investigators Discontinue Vibostolimab Combo in Resected Melanoma Trial

May 14th 2024

The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.

Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.
Selecting Observation Vs Immunotherapy in Advanced Melanoma

April 2nd 2024

Patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody can now receive lifileucel after accelerated approval from the FDA.
Accelerated Approval Given to Lifileucel in Metastatic Melanoma

February 16th 2024

The DermaSensor device demonstrates a high rate of sensitivity in the detection of more than 200 types of skin cancers in a clinical study.
FDA Clears Non-Invasive AI Device for Skin Cancer Detection

January 18th 2024

Results from a long-term analysis of the phase 3 IMCgp100-202 trial indicate that tebentafusp results in better disease control and long-lasting responses in those with HLA-A*02:01–positive, previously untreated metastatic uveal melanoma.
Tebentafusp Continues to Demonstrate Benefit in Metastatic Uveal Melanoma

January 4th 2024

Latest CME Events & Activities

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

<1
...
2324252627